Sooy, R., Han, J., Dafni, U., Cho, B., Yeo, C., Nadal, E., . . . Collaborators, E. 1. B. (2022). A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: The European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Citação norma ChicagoSooy, RA, et al. A Randomised Phase II Study of Osimertinib and Bevacizumab Versus Osimertinib Alone As Second-line Targeted Treatment in Advanced NSCLC With Confirmed EGFR and Acquired T790M Mutations: The European Thoracic Oncology Platform (ETOP 10-16) BOOSTER Trial. 2022.
Citação norma MLASooy, RA, et al. A Randomised Phase II Study of Osimertinib and Bevacizumab Versus Osimertinib Alone As Second-line Targeted Treatment in Advanced NSCLC With Confirmed EGFR and Acquired T790M Mutations: The European Thoracic Oncology Platform (ETOP 10-16) BOOSTER Trial. 2022.